Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Novel Neuroprotective Roles for the Alzheimer's Disease Risk Gene SORLA in Tau Pathology and Pathogenesis

Award Number: R01AG085498
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2028

Group Awards By:

View Award Description

Novel Neuroprotective Roles for the Alzheimer's Disease Risk Gene SORLA in Tau Pathology and Pathogenesis - Numerous mutational variants in the SORLA (SORL1) gene are associated with increased Alzheimer’s disease (AD) risk, and although growing evidence from our group and others support a neuroprotective role for SORLA in suppressing effects associated with Aβ, virtually nothing is known with respect to whether SORLA can modulate proteotoxic effects associated with tau. Here, we present evidence that transgenic upregulation of SORLA (“SORLA TG”) can reduce tau phosphorylation, as well as pathological ventricular dilation in 9 month- old (9MO) PS19 (P301S tau) mouse brain. Proteomic analysis reveals changes in proteomic profiles related to synaptic dysfunction and microglial activation, including upregulation of APOE and the complement component, C1q in PS19 mouse hippocampus; these changes were largely suppressed in SORLA TG/PS19 hippocampus, indicating that SORLA upregulation can potentially reverse pathological changes associated with tau proteotoxicity. Histological analysis indicates that C1q and astrogliosis is highly upregulated in PS19 hippocampus, and these effects were reduced in SORLA TG/PS19 animals. Interestingly, C1q has been previously shown to label synapses for microglial uptake and elimination in both J20 (hAPP) and PS19 mouse brain, which together, suggests that SORLA potentially mediates neuroprotective effects through suppression of deleterious changes associated with synaptic factors and gliosis in PS19 hippocampus. Our prior work also demonstrates that upregulation of a cleaved soluble SORLA (sSORLA) form in SORLA TG animals is also protective in neurons, and enhances neurite regeneration with neuronal injury. We therefore hypothesize that SORLA can mediate neuroprotective effects to limit tau pathology/proteotoxicity and determine here, whether and how SORLA overexpression, deletion or sSORLA can affect tau pathology and pathogenesis. As our results demonstrate that SORLA TG/PS19 animals can reverse pathological and proteomic features associated with late-stage (9MO) tau pathology, we will also characterize changes at early and mid- stages of tau pathology, and characterize cell-type specific transcriptomic changes in 9MO hippocampus in PS19 mice that may be potentially suppressed in SORLA TG/PS19 animals by snRNAseq analysis. We will also characterize effects of SORLA upregulation on glial-associated synaptic uptake and pruning in PS19 and SORLA TG/PS19 animals, and compare effects of intraneuronal tau dispersion from the MEC to DG region in wildtype (WT) vs SORLA TG brain using an AAV-tau propagation model used in our lab (Aim 1) (Zhu et al., 2022). We will also determine effects of SORLA deletion on tau pathology, gliosis and synpatotoxicity (Aim 2), and characterize effects of AD-associated SORLA mutational variants (T2134M, E2055X) that potentially upregulate sSORLA on microglial function and SORLA/sSORLA expression in an ESC-based human microglia cells in vitro, and in human microglial xenotransplant models in PS19/hMCSF mouse brain in vivo (Aim 3). Together, results from this study will provide insight into a previously undescribed role for SORLA and sSORLA in tau pathology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $877,445 )
2026	2026	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Aging Research	000	3	12/22/2025	NON-COMPETING CONTINUATION	$789,700
2026	2026	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Aging Research	001	3	2/26/2026	NON-COMPETING CONTINUATION	$87,745
														Subtotal = $877,445

Issue Date FY: 2025 ( Subtotal = $846,520 )
2025	2025	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Aging Research	000	2	11/25/2024	NON-COMPETING CONTINUATION	$777,415
2025	2025	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Aging Research	001	2	8/4/2025	NON-COMPETING CONTINUATION	$69,105
														Subtotal = $846,520

Issue Date FY: 2024 ( Subtotal = $867,695 )
2024	2024	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	10901 N TORREY PINES RD	LA JOLLA	CA	92037	SAN DIEGO	USA	Aging Research	000	1	11/22/2023	NEW	$867,695
														Subtotal = $867,695

Grand Total All Awards = $2,591,660

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel Neuroprotective Roles for the Alzheimer's Disease Risk Gene SORLA in Tau Pathology and Pathogenesis

Award Number: R01AG085498

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer